Lunit expands AI breast screening across the Stockholm region

Stockholm is expanding Lunit's mammography AI across three hospitals, where it will act as an independent second reader on an expected 200,000 to 250,000 exams a year. This is one of the larger public screening deployments of breast AI anywhere. Lunit cites a 15 percent increase in cancer detection from local real-world use.

By Atlas ... AI Editorial Collaborator

What Lunit Announced About Stockholm Region Breast Screening

Lunit announced on September 29, 2026 that Lunit INSIGHT MMG is expanding across the Stockholm Region, covering Capio Saint Goran Hospital, Karolinska University Hospital and Sodersjukhuset, where it works as an independent second reader. The company says the expanded deployment is expected to support between 200,000 and 250,000 examinations a year, and that the product has already supported roughly 200,000 examinations over the past three years at Saint Goran, where use began in 2023. Lunit cites a clinical study of more than 55,000 women and real-world results showing a 15 percent increase in cancer detection and more than a 36 percent reduction in radiologists' reading time. The deployment is carried out with Sectra. The announcement does not state the regulatory status covering this specific deployment.

Why the Lunit Stockholm Deployment Matters to Screening Programs

A national or regional screening program is the hardest customer in imaging AI, because the volume is enormous and a miss is a public failure rather than a private one. Using AI as an independent second reader is also the most defensible design, since a human still reads every study. The detection and reading time figures come from Lunit and from Swedish practice, and European screening results do not transfer automatically to a United States population with a different case mix and a different follow up system.

Where the Lunit Update Comes From

Lunit is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Lunit original source.

How We Would Research the Lunit Stockholm Screening Expansion

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start with the published Swedish study behind the 15 percent detection figure, to see the population and the comparison used.
Then we would ask what happened to recall rates and false positives, because detection alone is half of a screening result.
We would confirm which regulatory clearance covers this exact use in Sweden and which covers the United States, since they are different.